Information Library

Results for: Connect with investigators, regulators and physicians - North and Central America

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Hybrid Sales Solutions

    Hear from the Experts — April 19, 2011
    Joseph Chirillo, Senior Vice President, Commercialization, Strategic and Risk-Based Business, discusses the different challenges of reaching physicians in densely and sparsely populated areas.

  • Strange Bedfellows - Science, Business, Politics, and the Law - Risky Business, Chapter 2

    Hear from the Experts — February 2, 2011
    Chapter Two Excerpt from Risky Business: Managing the Quality of America’s Medicines by Robert A. Rhoades

  • QUINTILES AGAIN NAMED TO INFORMATIONWEEK 500

    Press Release — September 15, 2010 - Quintiles has again been named to the InformationWeek 500, the publication’s annual ranking of the nation’s most innovative users of business technology.

  • QUINTILES ANNOUNCES CLINICAL RESEARCH PARTNERSHIP WITH THE UNIVERSITY MALAYA MEDICAL CENTRE

    Press Release — July 5, 2010 - Quintiles announces a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its unique Prime Site program.

  • Malaysia Prime Site

    Video — July 2, 2010
    Adam Chasse, Sr. Director, Access to Patients explains the importance of Prime Sites and the impact of our clinical research partnership with the University of Malaya Medical Centre in Malaysia.

  • THE NEW HEALTH REPORT FINDS GREATER INFLUENCE FOR PATIENTS ON DRUG DEVELOPMENT

    Press Release — June 15, 2010 - Patients are emerging as an increasingly strong group when it comes to influencing the success and failure of new drugs – according to a newly published New Health Report commissioned by Quintiles.

  • New Frontiers

    Case Study — June 8, 2010
    By utilizing a deliberately flexible monitoring schedule, Quintiles was able to accommodate fluxes in enrollment and substantial variations in enrollment from site to site.

  • Commercial – Identify, Promote and Prove Treatment Value

    Brochure — April 1, 2010
    Quintiles has built an unmatched suite of commercial competencies that biopharma companies are leveraging for faster market access and sustained success.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

Page 1 of 1 (10 results)

Subscribe to Email Based on Your Interests

Set preferences